Chemotherapy efficacy in metastatic neuroendocrine colorectal cancer
https://doi.org/10.33878/2073-7556-2023-22-2-103-111
Abstract
AIM: to evaluate the effectiveness of first-line chemotherapy in patients with colorectal neuroendocrine cancer (NEC).
PATIENTS AND METHODS: a retrospective study included patients with metastatic colorectal NEC (2000-2020). The main analyzed parameter was the response rate to treatment according to the RECIST criteria, depending on the regimen used in the first line. The overall survival was additional parameter.
RESULTS: the study included 27 patients (13 with initial stage IV disease and 14 with progression after primary radical treatment). Ten patients in the 1st line underwent chemotherapy according to the EP scheme, 4 — XELOX, 2 — FOLFIRI, 2 — Irinotecan and Cisplatin, 1 — Samarium, 1 — Nivolumab, 1 — 5-FU-LV. Most often, the treatment effect (partial response or stabilization) was observed against the background of chemotherapy according to the EP scheme — in 60% of patients. The median OS was 7 months.
CONCLUSION: the use of chemotherapy according to the EP regimen is the preferred options for the treatment of metastatic colorectal NEC. The median OS in this group of patients remains extremely low, and new clinical trials are needed.
About the Authors
A. Seidinovich
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia; N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Kashirskoje Shosse, 24, Moscow, 115522, Russia
Ostrovityanova st., 1, Moscow, 117997, Russia
S. S. Gordeev
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia; Federal State Budgetary Educational Institution of Higher Education “Tyumen State Medical University” of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Sergey S. Gordeev — Candidate of Medical Sciences, Leading Researcher of the Oncology Department of Surgical Methods of Treatment No. 3 (Coloproctology)
Kashirskoje Shosse, 24, Moscow, 115522, Russia
Odesskaya st., 54, Tyumen, 625023, Russia
A. A. Markovich
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Alla A. Markovich — Candidate of Medical Sciences, p. n. With. Scientific Advisory Department
Kashirskoje Shosse, 24, Moscow, 115522, Russia
I. G. Komarov
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Igor G. Komarov — Doctor of Medical Sciences, Professor, Leading Researcher of the Surgical Department No. 5 (Endocrine Oncology)
Kashirskoje Shosse, 24, Moscow, 115522, Russia
D. V. Alexancev
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Denis V. Aleksantsev — resident of the 1st year of study in the specialty “Oncology”
Kashirskoje Shosse, 24, Moscow, 115522, Russia
Z. Z. Mamedli
N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Zaman Z. Mammedli — MD, PhD, Head of the Oncological Department of Surgical Methods of Treatment № 3 (Coloproctology)
Kashirskoje Shosse, 24, Moscow, 115522, Russia
References
1. Conte B, George B, Overman M, et al. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun;15(2):e1–7. Epub 2015 Dec 29. PMID: 26810202; PMCID: PMC4885752. doi: 10.1016/j.clcc.2015.12.007
2. Patta A, Fakih M. First-line Cisplatin Plus Etoposide in High-grade Metastatic Neuroendocrine Tumors of Colon and Rectum (MCRC NET). Review of 8 Cases. Anticancer Research. Mar 2011;31(3):975–978.
3. Frizziero M, et al. Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centers of excellence. Annals of Oncology. 2018;29:viii472.
4. Smith JD, Reidy DL, Goodman KA, et al. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014 Sep;21(9):2956–62. Epub 2014 Apr 24. PMID: 24763982; PMCID: PMC4521622. doi: 10.1245/s10434-014-3725-3
5. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3). The NORDIC NEC study. Ann Oncol. 2013 Jan;24(1):152–60. Epub 2012 Sep 11. doi: 10.1093/annonc/mds276
6. Balasubramanyam S, O’Donnell BP, Musher BL, et al. Evaluating treatment patterns for small cell carcinoma of the colon using the national cancer database (NCDB). J Gastrointest Cancer. 2018. doi: 10.1007/s12029-018-0054-y
7. Barsukov Yu.A., Kim D.F., Gutorov S.L., et al. Rare observation and tactics of treatment of recurrent neuroendocrine anal cancer. Pelvic surgery and oncology. 2012;(1):31–34. (in Russ.). doi: 10.17650/2220-3478-2012-0-1-31-34
8. Evdokimova E.V., Artamonova E.V., Delektorskaya V.V., et al. Tactics of treatment of a new subgroup of Grade 3 NEO in the first line of therapy. Medical Alphabet. 2021;(37):20–24. (in Russ.). doi: 10.33667/2078-5631-2021-37-20-24
9. Frizziero M, Chakrabarty B, Nagy B, et al. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. Journal of Clinical Medicine. 2020;9(1):273. doi: 10.3390/jcm9010273
10. Moreira AL, Ocampo PSS, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15(10):1599–1610.
11. Nagtegaal ID, Odze RD, Klimstra D, et al. WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182–
12. Epub 2019 Nov 13. PMID: 31433515; PMCID: PMC7003895. doi: 10.1111/his.13975
13. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016 Jul;62:132–7. Epub 2016 May 14. PMID: 27189322; PMCID: PMC5737828. doi: 10.1016/j.ejca.2016.03.081
14. Morizane C, et al. Effectiveness of etoposide and cisplatinvsirinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: The TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 2022 Aug 18; [e-pub]. doi: 10.1001/jamaoncol.2022.3395
Review
For citations:
Seidinovich A., Gordeev S.S., Markovich A.A., Komarov I.G., Alexancev D.V., Mamedli Z.Z. Chemotherapy efficacy in metastatic neuroendocrine colorectal cancer. Koloproktologia. 2023;22(2):103-111. https://doi.org/10.33878/2073-7556-2023-22-2-103-111
Views:
492
Email this article 
